Biology DivisionNumazu Branch

Publications

Description of Gelidibacter japonicus sp. nov., isolated from the Inland Sea (Setonaikai) in Japan.
H. Doi and I. Osawa
Archives of Microbiology 2019, doi:https://doi.org/10.1007/s00203-019-01668-2

Leucinostatin Y: A Peptaibiotic Produced by the Entomoparasitic Fungus Purpureocillium lilacinum 40-H-28.
I. Momose, T. Onodera, H. Doi, H. Adachi, M. Iijima, Y. Yamazaki, R. Sawa, Y. Kubota, M. Igarashi and M. Kawada
J. Nat. Prod. 2019, 82, 1120-1127

Potential anticancer activity of auranofin.
T. Onodera, I. Momose and M. Kawada
Chem. Pharm. Bull. 2019, 67, 186-191

Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection.
T. Ohishi, T. Masuda, H. Abe, C. Hayashi, H. Adachi, S. Ohba, M. Igarashi, T. Watanabe, H. Mimuro, E. Amalia, DK. Inaoka, K. Mochizuki, K. Kita, M. Shibasaki and M. Kawada
Helicobacter 2018, 23, e12470

A guanine derivative as a new MEK inhibitor produced by Streptomyces sp. MK63-43F2.
M. Iijima, Yuji Kubota, R. Sawa, Yumiko Kubota, M. Hatano, M. Igarashi, M. Kawada, I. Momose, M. Takekawa and M. Shibasaki
J. Antibiot. 2018, 71, 135-138

Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.
H. Adachi, K. Nakae, S. Sakamoto, C. Nosaka, S. Atsumi, M. Shibuya, N. Higashi, M. Nakajima, T. Irimura and Y. Nishimura
J. Antibiot. 2018, 71, 60-71

Novel approaches for identification of anti-tumor drugs and new bioactive compounds.
M. Kawada, S. Atsumi, S. Wada and S. Sakamoto
J. Antibiot. 2018, 71, 39-44

Phenazine carboxylic acid and its derivative induce osteoblast differentiation in preosteoblastic MC3T3-E1 cells but adipocyte differentiation in pluripotent mesenchymal C3H10T1/2 cells.
S. Sakamoto, T. Watanabe, Y. Kohda, M. Iijima, R. Sawa, M. Okada, H. Adachi, Y. Nishimura, M. Kawada
J. Antibiot. 2017, 70, 1146-1149

Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2.
I. Momose and T. Watanabe
J. Antibiot. 2017, 70, 542-550.

Acremopeptin, a new peptaibol from Acremonium sp. PF1450.
M. Iijima, M. Amemiya, R. Sawa, Y. Kubota, T. Kunisada, I. Momose, M. Kawada and M. Shibasaki
J. Antibiot. 2017, 70, 791-794

Vibrio japonicus sp. nov.,a novel member of the Nereis clade in the genus Vibrio isolated from the coast of Japan.
H. Doi, I. Osawa, H. Adachi and M. Kawada
PLoS ONE 12(2):e0172164. 2017, doi: 10.1371/journal.pone.0172164

A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo
M. Kawada, H. Inoue, M. Kajikawa, M. Sugiura, S. Sakamoto, S. Urano, C. Karasawa, I. Usami, M. Futakuchi and T. Masuda.
Sci. Rep. 2017, 7:40400 doi: 10.1038/srep40400.

Small molecules modulating tumor-stromal cell interactions: new candidates for anti-tumor drugs.
M. Kawada
J. Antibiot. 2016, 69, 411-414.

An iminosugar-based heparanase inhibitor heparastatin (SF4) suppresses infiltration of neutrophils and monocytes into Inflamed dorsal air pouches.
M. Sue, N. Higashi, H. Shida, Y. Kogane, Y. Nishimura, H. Adachi, E. Kolaczkowska, M. Kepka, M. Nakajima and T. Irimura
Int. immunopharmacology. 2016, 35, 15-21.

Biological activities of unique isoflavones prepared from Apios americana Medik.
H. Kaneta, M. Koda, S. Saito, M. Imoto, M. Kawada, Y. Yamazaki, I. Momose and K. Shindo.
Biosci Biotechnol Biochem. 2016, 80, 774-778.

Synthesis of androprostamine A and resormycin.
H. Abe, Y. Yamazaki, C. Sakashita, I. Momose, T. Watanabe and M. Shibasaki.
Chem. Pharm. Bull. 2016, 64, 982-987.

Heparanase augments inflammatory chemokine production from colorectal carcinoma cell lines.
N. Tsunekawa, N. Higashi, Y. Kogane, M. Waki, H. Shida, Y. Nishimura, H. Adachi, M. Nakajima and T. Irimura.
Biochem. Biophys. Res. Commun. 2016,469,873-883.

Report on the use of non-clinical studies in the regulatory evalution of oncology drugs.
Y. Hayakawa, M. Kawada, H. Nishikawa, T. Ochiya, H. Saya, H. Seimiya, R. Yao, M. Hayashi, C. Kai, A. Matsuda, T. Naoe, A. Ohtsu, T. Okazaki, H. Saji, M. Sata, H. Sugimura, Y. Sugiyama, M. Toi and T. Irimura.
Cancer Sci. 2016, 107, 189-202.

The therapeutic potential of microbial proteasome inhibitors.
I. Momose and M. Kawada.
Int Immunopharmacol. 2016, 37, 23-30.

Coccoquinones A and B, new anthraquinone derivatives produced by Staphylotrichum coccosporum PF1460
D. Tatsuda, M. Amemiya, R. Sawa, K. Sumiyoshi, T. Watanabe, I. Momose, M. Kawada, A. Nomoto and M. Shibasaki.
J. Antibiot. 2016, 69, 176-178.

A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
M. Ohira, Y. Iwasaki, C. Tanaka, M. Kuroki, N. Matsuo, T. Kitamura, M. Yukuhiro, H. Morimoto, N. Pang, B. Liu, T. Kiyono, M. Amemiya, K. Tanaka, K. Yoshida, N. Sugimoto, T. Ohshima and M. Fujita.
Biochim Biophys Acta. 2015, 1850, 1676-1684

がんと間質の相互作用を利用したがんの抑制
川田 学、吉田潤次郎、坂本修一
実験医学(増刊)2015, 33, 199-203

New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
S. Sakamoto, H. Inoue, S. Ohba, Y. Kohda, I. Usami, T. Masuda, M. Kawada and A. Nomoto.
Cancer Science.2015,106,367-374

Quinofuracins A-E, produced by the fungus staphylotrichum boninense PF1444, show p53-dependent growth suppression.
D. Tatsuda, I. Momose, T. Someno, R. Sawa, Y. Kubota, M. Iijima, T. Kunisada, T. Watanabe, M. Shibasaki and A. Nomoto.
J. Nat. Prod. 2015,78,188-195

Complete stereochemistry and preliminary structure-activity relationship of rakicidin A,
a hypoxia-selective cytotoxin from micromonospora sp.
N. Oku, S. Matoba, YM. Yamazaki, R. Shimasaki, S. Miyanaga and Y. Igarashi.
J. Nat. Prod. 2014, 77, 2561-2565.

Antitumor effects of tyropeptin-boronic acid derivatives: new proteasome inhibitors.
I. Momose, H. Abe, T. Watanabe, S. Ohba, K. Yamazaki, S. Dan, T. Yamori, T. Masuda and
A. Nomoto
Cancer Sci. 2014, 105, 1609-1615.

Androprostamines A and B, the new anti-prostate cancer agents produced by Streptomyces sp. MK932-CF8.
Y. Yamazaki, T. Someno, M. Igarashi, N. Kinoshita, M. Hatano, M. Kawada, I.Momose and
A. Nomoto.
J. Antibiot. 2014, 68, 279-285

Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrate.
M. Takemoto, Y. Kawamura, M. Hirohama, Y. Yamaguchi, H. Handa, H. Saitoh, Y. Nakao,
M Kawada, K. Khalid, H. Koshino, K. Kimura, A. Ito and M. Yoshida.
J. Antibiot. 2014, 67, 335-338.

Modulation of tumor-stromal cell interactions: a new anti-tumor strategy targeting the tumor microenvironment.
M. Kawada, S. Sakamoto and A. Nomoto.
Forum on Immunopathological Diseases and Therapeutics 2013, 4, 53-62.

がん-間質相互作用を介したがん細胞の増殖抑制
川田学、坂本修一
Medical Science Digest 2013, 39, 24-27.

Synthesis of intervenolin, an antitumor natural quinolone with unusual substituents.
H. Abe, M. Kawada, H. Inoue, S. Ohba, A. Nomoto, T. Watanabe and M. Shibasaki.
Org. Lett. 2013, 15, 2124-2127.

Structure-activity relationship study of intervenolin derivatives:
synthesis, antitumor and anti-Helicobacter Pylori activities.
H. Abe, M. Kawada, H. Inoue, S. Ohba, T. Masuda, C. Hayashi, M. Igarashi,
A. Nomoto, T. Watanabe and M. Shibasaki.
Tetrahedron 2013, 69, 7608-7617.

Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2.
M. Kawada, H. Inoue, S. Ohba, M. Hatano, M. Amemiya, C. Hayashi, I. Usami, H. Abe, T. Watanabe, N. Kinoshita, M. Igarashi, T. Masuda, D. Ikeda and A. Nomoto.
J. Antibiot. 2013, 66, 543-548.

Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase.
R. Sawa, Y. Takahashi, H. Hashizume, K. Sasaki, Y. Ishizaki, M.Umekita, M. Hatano,
H. Abe, T. Watanabe, N. Kinoshita, Y. Homma, C. Hayashi, K. Inoue, S. Ohba,
T. Masuda,  M. Arakawa, Y. Kobayashi, M. Hamada, M. Igarashi, H. Adachi,
Y. Nishimura and Y. Akamatsu.
Chem. Eur. J. 2012, 18, 15772-15781.

In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
I. Momose, D. Tatsuda, S. Ohba, T. Masuda, D. Ikeda and A. Nomoto.
Cancer Sci. 2012, 103, 1730-1736.

Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
K. Kimura, Y. Sakamoto, N. Fujisawa, S. Uesugi, N. Aburai, M. Kawada,
S. Ohba, T. Yamori, E. Tsuchiya and H. Koshino.
Bioorg. Med. Chem. 2012, 20, 3887-3897.

Decalpenic acid induces early osteoblastic markers in pluripotent mesenchymal cells via activation of retinoic acid receptor gamma.
S. Sakamoto, F. Kojima, I. Momose, M. Kawada, H. Adachi and Y. Nishimura.
Biochem. Biophys. Res. Commun. 2012, 422, 751-757.

Decalpenic acid, a novel small molecule from Penicillium verruculosum CR37010, induces early osteoblastic markers in pluripotent mesenchymal cells.
S. Sakamoto, F. Kojima, M. Igarashi, R. Sawa, M. Umekita, Y. Kubota, K. Nakae,
S. Yamaguchi, H. Adachi, Y. Nishimura and Y. Akamatsu.
J. Antibiot. 2010, 63, 703-708.

Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells.
M. Iijima, I. Momose and D. Ikeda.
Biosci. Biotechnol. Biochem. 2010, 74, 1913-1919.

Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome
inhibitors.
T. Watanabe, H. Abe, I. Momose, Y. Takahashi, D. Ikeda and Y. Akamatsu.
Bioorg. Med. Chem. Lett. 2010, 20, 5839-5842.

Citric acid inhibits a bacterial ceramidase and alleviates atopic dermatitis in an animal
model.
H. Inoue, T. Someno, M. Kawada and D. Ikeda.
J. Antibiot. 2010, 63, 611-613.

NBRI16716A, a new antitumor compound against human prostate cancer cells, produced by Perisporiopsis melioloides Mer-f16716.
M. Kawada, T. Someno, H. Inoue, S. Ohba, T. Masuda, T. Kato and D. Ikeda.
J. Antibiot. 2010, 63, 319-323.

NBRI17671, a new antitumor compound, produced by Acremonium sp. CR17671.
M. Kawada, I. Usami, T. Someno, T. Watanabe, H. Abe, H. Inoue, S. Ohba, T. Masuda,
Y. Tabata, S. Yamaguchi and D. Ikeda.
J. Antibiot. 2010, 63, 237-243.

Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions.
I. Momose, S. Ohba, D. Tatsuda, M. Kawada, T. Masuda, G. Tsujiuchi, T. Yamori,
H. Esumi and D. Ikeda.
Biochem. Biophys. Res. Commun. 2010, 392, 460-466.

Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses
cancer metastasis.
S. Wada, I. Usami, Y. Umezawa, H. Inoue, S. Ohba, T. Someno, M. Kawada and
D. Ikeda.
Cancer Sci. 2010, 101, 743-750.

Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells.
M. Kawada, H. Inoue, S. Ohba, T. Masuda, I. Momose and D. Ikeda.
Int. J. Cancer 2010, 126, 810-818.

TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma
cells.
M. Iijima, I. Momose and D. Ikeda.
Anticancer Res. 2009, 29, 977-985.

Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
T. Watanabe, I. Momose, M. Abe, H. Abe, R. Sawa, Y. Umezawa, D. Ikeda,
Y. Takahashi and Y. Akamatsu.
Bioorg. Med. Chem. Lett. 2009, 19, 2343-2345.

New atpenins, NBRI23477 A and B, inhibit the growth of human prostate cancer cells.
M. Kawada, I. Momose, T. Someno, G. Tsujiuchi and D. Ikeda.
J. Antibiot. 2009, 62, 243-246.

Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells.
I. Momose, S. Kunimoto, M. Osono and D. Ikeda.
Biochem. Biophys. Res. Commun. 2009, 380, 171-176.

Ceramidastin, a novel bacterial ceramidase inhibitor, produced by Penicillium sp.
Mer-f17067.
H. Inoue, T. Someno, T. Kato, H. Kumagai, M. Kawada and D. Ikeda.
J. Antibiot. 2009, 62, 63-67.

Phthoxazolin A inhibits prostate cancer growth by modulating tumor-stromal cell
interactions.
M. Kawada, H. Inoue, I. Usami and D. Ikeda.
Cancer Sci. 2009, 100, 150-157.

A new terrein glucoside, a novel inhibitor of angiogenin secretion in tumor angiogenesis.
M. Arakawa, T. Someno, M. Kawada and D. Ikeda.
J. Antibiot. 2008, 61, 442-448.

Transforming growth factor-β1 modulates tumor-stromal cell interactions of prostate
cancer through insulin-like growth factor-I.
M. Kawada, H. Inoue, M. Arakawa and D. Ikeda.
Anticancer Res. 2008, 28, 721-730.